1. The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida

2. PHARMACOKINETICS what the body does to the drug PHARMACODYNAMICS what the drug does to the body

3. Pharmacokinetics conc. vs time Conc. Time 025 0.0 0.4 PK/PD effect vs time Time Effect 0 1 025 Pharmacodynamics conc. vs effect 0 1 10 -4 10 -3 Conc (log) Effect

4. Pharmacokinetics the time course of drug and metabolite concentrations in the body

5. Pharmacokinetics helps to optimize drug therapy:  dose  dosage regimen  dosage form

6. What happens to a drug after its administration ? ("Fate of drug") Liberation Absorption Distribution Metabolism Excretion

7. Clearance Volume of distribution Half-life Bioavailability Protein Binding Pharmacokinetic Parameters

8. Clearance quantifies ELIMINATION is the volume of body fluid cleared per time unit (L/h, mL/min) is usually constant

9. Clearance Eliminating Organ CL = Q·E QBlood Flow EExtraction Ratio

10. Clearance Parameters: Blood Flow, intrinsic clearance, protein binding Good prediction of changes in clearance Steady state Q CiCi CoCo Eliminating Organ

11. High-extraction drugs Low-extraction drugs

12. Clearance Clearance can be calculated from Excretion rate / Concentration e.g. (mg/h) / (mg/L) = L/h Dose / Area under the curve (AUC) e.g. mg / (mg·h/L) = L/h

13. Clearance Total body clearance is the sum of the individual organ clearances CL = CL ren + CL hep + CL other

14. Volume of Distribution - quantifies DISTRIBUTION - relates drug concentration (Cp) to amount of drug in the body (X) - gives information on the amount of drug distributed into the tissues Vd = X / Cp

15. Apparent Volume of Distribution X V C 2 = X / Vd Vd = X / C 2 X V C 1 = X / V V = X / C 1 C1C1 C2C2 C 1 > C 2 V < Vd

16. Volume of Distribution Dicloxacillin0.1 L/kg Gentamicin (ECF)0.25 L/kg Antipyrine (TBW)0.60 L/kg Ciprofloxacin1.8 L/kg Azithromycin31 L/kg

17. Half-Life Half-life is the time it takes for the concentration to fall to half of its previous value Half-life is a secondary pharmacokinetic parameter and depends on clearance and volume of distribution

18. Half-Life kelimination rate constant CLclearance Vdvolume of distribution

19. Bioavailability f is the fraction of the administered dose that reaches the systemic circulation - quantifies ABSORPTION

20. Bioavailability Rate and Extent of Absorption

21. Protein Binding reversibe vs. irreversible linear vs. nonlinear rapid equilibrium The free (unbound) concentration of the drug at the receptor site should be used in PK/PD correlations to make prediction for pharmacological activity

23. vascular spaceextravascular space plasma protein binding blood cell binding, diffusion into blood cells, binding to intracellular biological material tissue cell binding, diffusion into tissue cells, binding to intracellular biological material binding to extracellular biological material

24. Interstitium Capillary Cell Perfusate Dialysate Microdialysis

26. Pharmacokinetic profile of cefpodoxime (400 mg oral dose, n = 6)

27. Pharmacokinetic profile of cefixime (400 mg oral dose, n = 6) Mean ± SD

28. Pharmacokinetics

29. Two-compartment model XpXp E D k 12 Dose X c Drug in the central compartment X p Drug in the peripheral compartment Drug eliminated XcXc k 10 k 21

30. Two-compartment model

31. Short-term infusion

32. Three-compartment model XpXp E D k 12 DDose EDrug eliminated XcXc k 10 k 21 k 31 k 13 XpXp s d X c Drug in the central compartment X ps Drug in the shallow peripheral compartment X pd Drug in the deep peripheral compartment

34. Drug Delivery Pharmacokinetics Pharmacodynamics Biopharmaceutics PK-PD-Modeling ? ?

36. Questions What are the effects of protein binding on antibiotic activity and interpretation of plasma levels? What are the effects of a change in protein binding on unbound concentrations? Why do we monitor post-distribution peaks as indicators of aminoglycoside activity? Why do we monitor troughs as indicators of aminoglycoside toxicity? How do you interpret a high tissue level of a macrolide?

37. Compartment Models Parameters: Rate constants, intercepts Linear and nonlinear regression Complete concentration-time-profiles Steady-state and non-steady-state

38. Intravenous bolus XE D k DDose XDrug in the body EDrug eliminated One compartment model

39. Intravenous bolus Plasma concentration (single dose) DDose C 0 Initial Concentration VdVolume of Distribution

40. Normal Plot Semilogarithmic Plot Intravenous bolus

41. Plasma concentration (multiple dose, steady state) Peak Trough

42. Intravenous bolus Multiple Dose

43. First-order absorption A E D k Dose Drug at absorption site Drug in the body Drug eliminated X k a f One compartment model

44. Oral administration Plasma concentration (single dose)

45. Oral administration

46. Average concentration (multiple dose, steady state)

47. Oral administration Multiple Dose

48. One compartment model A E D k Dose Drug at absorption site Drug in the body Drug eliminated X R 0 f Zero-order absorption

49. Constant rate infusion Plasma concentration (during infusion)

50. Constant rate infusion

51. Plasma concentration (steady state)

52. Two-compartment model Plasma concentration (single i.v. bolus dose)  -phase:distribution phase  -phase:elimination phase

53. Two-compartment model

54. XpXp XcXc XpXp XcXc XpXp XcXc initiallysteady stateelimination phase Volume of distribution

55. Significance of Pharmacokinetic Parameters for Dosing Maintenance Dose Loading Dose Fluctuation Dosing Interval